Affiliation: Washington University School of Medicine
- Once-daily antiretroviral therapies for HIV infection: Consensus Statement of an Advisory Committee of the International Association of Physicians in AIDS CareCalvin Cohen
CRI New England, 23 Miner Street, Boston, Massachusetts 02215 3318, USA
J Int Assoc Physicians AIDS Care (Chic) 1:141-5. 2002..The opinions expressed in this Consensus Statement represent only those of the Advisory Committee...
- Effects of potent antiretroviral therapy on free testosterone levels and fat-free mass in men in a prospective, randomized trial: A5005s, a substudy of AIDS Clinical Trials Group Study 384Michael P Dube
Division of Infectious Diseases, Indiana University, Indianapolis, USA
Clin Infect Dis 45:120-6. 2007..The effects of initiation of different antiretroviral regimens on testosterone levels and changes in fat-free mass have not been reported...
- Subgroup analyses of maraviroc in previously treated R5 HIV-1 infectionGerd Fatkenheuer
Universitätsklinik Köln, Cologne, Germany
N Engl J Med 359:1442-55. 2008....
- Effect of prolonged discontinuation of successful antiretroviral therapy on CD4+ T cell decline in human immunodeficiency virus-infected patients: implications for intermittent therapeutic strategiesPablo Tebas
Washington University School of Medicine, St Louis, Missouri 63108, USA
J Infect Dis 186:851-4. 2002..In a multiple regression analysis model, the increase of CD4(+) T cells while receiving therapy and age were independently associated with the rate of CD4(+) T cell loss...
- Accelerated bone mineral loss in HIV-infected patients receiving potent antiretroviral therapyP Tebas
Department of Medicine, Washington University School of Medicine, St Louis, Missouri 63108, USA
AIDS 14:F63-7. 2000..The use of highly active antiretroviral therapy (HAART) has been associated with multiple metabolic complications whose pathogenesis is poorly understood at the present time...
- Nelfinavir mesylateP Tebas
Division of Infectious Diseases, Washington University School of Medicine, Box 8051, St Louis, MO 63110, USA
Expert Opin Pharmacother 1:1429-40. 2000..The results of small, non-controlled trials suggest these failures can be rescued with a second protease-based regimen. Due to the above characteristics, nelfinavir has become the most frequently prescribed first line PI...
- Timing of antiretroviral therapy. Use of Markov modeling and decision analysis to evaluate the long-term implications of therapyP Tebas
Division of Infectious Diseases, Department of Medicine, Washington University School of Medicine, St Louis, Missouri 63108, USA
AIDS 15:591-9. 2001..The timing of initiation of antiretroviral therapy is controversial. Current guidelines are heavily based on the principle of 'hit early, hit hard', although the long-term implications of this approach are unknown...
- Resistance exercise training reduces hypertriglyceridemia in HIV-infected men treated with antiviral therapyK E Yarasheski
Division of Metabolism, Endocrinology and Diabetes, Washington University Medical School, St Louis, Missouri 63110, USA
J Appl Physiol 90:133-8. 2001..02). These findings imply that resistance exercise training-induced muscle hypertrophy may promote triglyceride clearance from the circulation of hypertriglyceridemic HIV-infected men treated with antiviral therapy...
- Insulin resistance in HIV protease inhibitor-associated diabetesK E Yarasheski
Division of Endocrinology, Diabetes, and Metabolism, Washington University Medical School, St Louis, Missouri 63110, USA
J Acquir Immune Defic Syndr 21:209-16. 1999..Fasting hyperglycemia has been associated with HIV protease inhibitor (PI) therapy...
- Nelfinavir, a new protease inhibitor: early clinical resultsW G Powderly
Division of Infectious Diseases, Washington University School of Medicine, St Louis, Missouri 63110, USA
AIDS 13:S41-8. 1999..Thus, initial trials indicate that nelfinavir is equivalent to other potent protease inhibitors and can be considered as a component in first-line combination therapy for HIV-infected patients...
- Similar efficacy and tolerability of atazanavir compared with atazanavir/ritonavir, each with abacavir/lamivudine after initial suppression with abacavir/lamivudine plus ritonavir-boosted atazanavir in HIV-infected patientsKathleen E Squires
Division of Infectious Diseases, Jefferson Medical College, Thomas Jefferson University, Philadelphia, Pennsylvania 19107, USA
AIDS 24:2019-27. 2010....
- Increasing prevalence of resistance mutations in antiretroviral-naïve individuals with established HIV-1 infection from 1996-2001 in St. LouisM B Ristig
Division of Infectious Diseases, Department of Internal Medicine, Washington University School of Medicine, St Louis, Missouri 63108, USA
HIV Clin Trials 3:155-60. 2002..Prevalence in chronically infected antiretroviral-naïve patients is reportedly low. Routine genotyping in this population is not recommended...
- Randomized open-label trial of two simplified, class-sparing regimens following a first suppressive three or four-drug regimenMargaret A Fischl
AIDS Clinical Research Unit R 60A, Department of Medicine, University of Miami School of Medicine, 1800 NW 10th Avenue, Miami, FL 33136, USA
AIDS 21:325-33. 2007..Complex antiretroviral regimens can be associated with increased toxicity and poor adherence. Our aim was to compare the efficacy and safety of switching to two simplified, class-sparing antiretroviral regimens...
- Cardiovascular risks of antiretroviral therapiesKristin Mondy
Washington University School of Medicine, Saint Louis, Missouri 63110, USA
Annu Rev Med 58:141-55. 2007..Optimal selection of metabolically neutral antiretroviral therapies, together with aggressive management of other modifiable coronary risk factors, may improve cardiovascular disease risk in the long term...
- Prevalence, risk factors, and outcomes for occult hepatitis B virus infection among HIV-infected patientsVincent Lo Re
Division of Infectious Diseases, Department of Medicine, University of Pennsylvania School of Medicine, 423 Guardian Drive, Philadelphia, PA 19104, USA
J Acquir Immune Defic Syndr 44:315-20. 2007..The prevalence of occult HBV in HIV-infected patients remains controversial, and the risk factors and clinical significance are unknown...
- Explaining, predicting, and treating HIV-associated CD4 cell loss: after 25 years still a puzzleW Keith Henry
JAMA 296:1523-5. 2006
- A pilot study evaluating time to CD4 T-cell count <350 cells/mm(3) after treatment interruption following antiretroviral therapy +/- interleukin 2: results of ACTG A5102Keith Henry
HIV Program, Hennepin County Medical Center and the University of Minnesota, Minneapolis, MN 55415, USA
J Acquir Immune Defic Syndr 42:140-8. 2006..By boosting CD4 T-cell counts, interleukin 2 (IL-2) could safely prolong the duration of treatment interruption (TI) in a CD4-driven strategy...
- Mixed patterns of changes in central and peripheral fat following initiation of antiretroviral therapy in a randomized trialKathleen Mulligan
Department of Medicine, Division of Endocrinology, San Francisco General Hospital, University of California at San Francisco, San Francisco, CA, USA
J Acquir Immune Defic Syndr 41:590-7. 2006..We examined intraindividual changes in dual-energy x-ray absorptiometry (DEXA) and anthropometry data over 64 weeks after initiation of antiretroviral therapy (ART)...
- Management of potential neurocysticercosis in patients with HIV infectionSashank Prasad
Department of Neurology, University of Pennsylvania, Philadelphia, PA, USA
Clin Infect Dis 42:e30-4. 2006..We report 3 cases and suggest including the CD4+ T lymphocyte count as an important factor in the proper diagnosis and treatment of patients with human immunodeficiency virus and potential neurocysticercosis...
- Associations among race/ethnicity, ApoC-III genotypes, and lipids in HIV-1-infected individuals on antiretroviral therapyAndrea S Foulkes
School of Public Health and Health Sciences, University of Massachusetts, Amherst, Massachusetts, United States of America
PLoS Med 3:e52. 2006..However, the association of race/ethnicity, or candidate gene effects across race/ethnicity, with plasma lipid levels in HIV-1-infected individuals, has not been reported...
- Bone disease and HIV infectionValerianna Amorosa
Division of Infectious Diseases, University of Pennsylvania School of Medicine, Philadelphia, PA, USA
Clin Infect Dis 42:108-14. 2006....
- [Delayed diagnosis of HIV infection in the Spanish VACH cohort [1997-2002]]Ramón Teira Cobo
Servicio de Enfermedades Infecciosas, Hospital de Basurto, Bilbao, Espana
Gac Sanit 21:66-9. 2007..To study the prevalence of delayed diagnosis of HIV infection and associated factors...
- The virologic, immunologic, and clinical effects of interleukin 2 with potent antiretroviral therapy in patients with moderately advanced human immunodeficiency virus infection: a randomized controlled clinical trial--AIDS Clinical Trials Group 328Ronald Mitsuyasu
Department of Internal Medicine, University of California Los Angeles, USA
Arch Intern Med 167:597-605. 2007..Interleukin 2 (IL-2) administration increases CD4 counts in persons with higher counts. This study investigated persons with moderately advanced human immunodeficiency virus infection receiving highly active antiretroviral therapy (HAART)...
- Maraviroc for previously treated patients with R5 HIV-1 infectionRoy M Gulick
Weill Cornell Medical College, New York, NY 10065, USA
N Engl J Med 359:1429-41. 2008..CC chemokine receptor 5 antagonists are a new class of antiretroviral agents...
- The use of HAART is associated with decreased risk of death during initial treatment of cryptococcal meningitis in adults in BotswanaGregory P Bisson
Department of Medicine, University of Pennsylvania School of Medicine, 423 Guardian Drive, Philadelphia, PA 19104, USA
J Acquir Immune Defic Syndr 49:227-9. 2008..The objective of this study was to evaluate outcomes among adults with a first episode of cryptococcal meningitis (CM), comparing those on highly active antiretroviral therapy (HAART) with those not on HAART...
- Genetic analysis implicates resistin in HIV lipodystrophyKoustubh Ranade
Bristol Myers Squibb R and D, Princeton, New Jersey 08543 5400, USA
AIDS 22:1561-8. 2008..To investigate the role of genetic variation in influencing the risk of metabolic complications associated with highly active antiretroviral therapy (HAART)...
- Metabolic and immune activation effects of treatment interruption in chronic HIV-1 infection: implications for cardiovascular riskPablo Tebas
University of Pennsylvania, Philadelphia, Pennsylvania, United States of America
PLoS ONE 3:e2021. 2008..Our goal was to evaluate fasting metabolic changes associated with interruption of antiretroviral therapy and relate them to changes of immune activation markers and cardiovascular risk...
- Hemochromatosis gene polymorphisms, mitochondrial haplogroups, and peripheral lipoatrophy during antiretroviral therapyTodd Hulgan
Division of Infectious Diseases, Vanderbilt University School of Medicine, Nashville, Tennessee 37203, USA
J Infect Dis 197:858-66. 2008..Mitochondrial haplogroups and hemochromatosis gene (HFE) polymorphisms have been associated with ART-induced neuropathy. We assessed relationships between these variants and lipoatrophy...
- Alendronate with calcium and vitamin D supplementation is safe and effective for the treatment of decreased bone mineral density in HIVGrace A McComsey
Rainbow Babies and Children s Hospital and Case Western Reserve University, Cleveland, Ohio, USA
AIDS 21:2473-82. 2007..Bisphosphonates are currently the mainstay of treatment for postmenopausal and male osteoporosis in HIV-uninfected individuals; however, their efficacy and safety in HIV-infected patients remains unclear...
- Long-term body fat outcomes in antiretroviral-naive participants randomized to nelfinavir or efavirenz or both plus dual nucleosides. Dual X-ray absorptiometry results from A5005s, a substudy of Adult Clinical Trials Group 384Michael P Dube
Division of Infectious Diseases, Indiana University, Indianapolis, USA
J Acquir Immune Defic Syndr 45:508-14. 2007..Long-term regional body fat outcomes have not been well described in randomized antiretroviral drug trials...
- Glucose metabolism, lipid, and body fat changes in antiretroviral-naive subjects randomized to nelfinavir or efavirenz plus dual nucleosidesMichael P Dube
Division of Infectious Diseases, Indiana University, Indianapolis, Indiana, USA
AIDS 19:1807-18. 2005..To determine if particular components of antiretroviral drug regimens are associated with greater insulin resistance, dyslipidemia, and peripheral lipoatrophy...
- Distinct mechanisms of T cell reconstitution can be identified by estimating thymic volume in adult HIV-1 diseaseRobert C Kalayjian
Division of Infectious Diseases, MetroHealth Medical Center and Case Western Reserve University, Cleveland, Ohio 44109 1998, USA
J Infect Dis 192:1577-87. 2005..We have attempted to identify factors associated with T cell reconstitution in response to highly active antiretroviral therapy...
- Visceral adiposity, C-peptide levels, and low lipase activities predict HIV-dyslipidemiaKevin E Yarasheski
Division of Endocrinology, Metabolism and Lipid Research, Washington University Medical School, 660 South Euclid Avenue, Box 8127, St Louis, MO 63110, USA
Am J Physiol Endocrinol Metab 285:E899-905. 2003..g., central adiposity and hyperinsulinemia) and mediated only partially by factors that influence triglyceride clearance (e.g., lipase activity)...
- Fat redistribution and bone abnormalities in HIV-infected patientsPablo Tebas
Washington University, 4511 Forest Park, Suite 304, Saint Louis, MO 63108, USA
J Int Assoc Physicians AIDS Care (Chic) 2:59-65. 2003
- Nonnucleoside reverse transcriptase inhibitor resistance among antiretroviral-naive HIV-positive pregnant womenSalome N Juethner
Division of Infectious Diseases, Washington University School of Medicine, St Louis, Missouri 63108, USA
J Acquir Immune Defic Syndr 32:153-6. 2003....
- Early intensification with abacavir in subjects at high risk for incomplete viral suppressionJohn A Bartlett
Antivir Ther 8:361-3. 2003
- Granulocyte-macrophage colony-stimulating factor induces modest increases in plasma human immunodeficiency virus (HIV) type 1 RNA levels and CD4+ lymphocyte counts in patients with uncontrolled HIV infectionJeffrey M Jacobson
Department of Medicine, Beth Israel Medical Center and Albert Einstein College of Medicine, New York, New York 10003, USA
J Infect Dis 188:1804-14. 2003..Studies have reported that plasma human immunodeficiency virus type 1 (HIV-1) RNA levels and CD4+ lymphocyte counts in HIV-infected patients improved after treatment with granulocyte-macrophage colony-stimulating factor (GM-CSF)...
- Evaluation of the virological and metabolic effects of switching protease inhibitor combination antiretroviral therapy to nevirapine-based therapy for the treatment of HIV infectionPablo Tebas
Washington University School of Medicine, St Louis, Missouri 63110, USA
AIDS Res Hum Retroviruses 20:589-94. 2004..Our study supports a pathogenic role for PIs in the development of hypertriglyceridemia and insulin resistance, but a more limited role in the fat redistribution syndrome...
- Emerging bone problems in patients infected with human immunodeficiency virusKristin Mondy
Division of Infectious Diseases, AIDS Clinical Trials Unit, Washington University School of Medicine, St Louis, Missouri 63110, USA
Clin Infect Dis 36:S101-5. 2003..Hormone replacement and antiresorptive therapies might be also indicated...
- A tale of 2 epidemics: the intersection between obesity and HIV infection in PhiladelphiaValerianna Amorosa
Division of Infectious Diseases, University of Pennsylvania, Philadelphia, PA 19104 6073, USA
J Acquir Immune Defic Syndr 39:557-61. 2005..Obesity and HIV infection are ongoing epidemics in the United States. Obesity predisposes to diabetes and cardiovascular disease, which are complications also associated with HIV and/or its treatment...
- On antiretroviral guidelines and evidence based medicinePablo Tebas
Enferm Infecc Microbiol Clin 20:241-3. 2002
- Alendronate, vitamin D, and calcium for the treatment of osteopenia/osteoporosis associated with HIV infectionKristin Mondy
Washington University School of Medicine, Division of Infectious Diseases, St Louis, MO, USA
J Acquir Immune Defic Syndr 38:426-31. 2005..We conducted a 48-week prospective, randomized, open-label study to evaluate the effects of alendronate, vitamin D, and calcium supplementation on bone mineral density (BMD) in patients with HIV infection...
- A phase II randomized study of the virologic and immunologic effect of zidovudine + stavudine versus stavudine alone and zidovudine + lamivudine in patients with >300 CD4 cells who were antiretroviral naive (ACTG 298)Richard B Pollard
University of California Davis Medical Center, Patient Support Services Building, 4150 V Street, Suite G500, Sacramento, CA 95817, USA
AIDS Res Hum Retroviruses 18:699-704. 2002..Based on this study and other data, combining d4T and ZDV is not recommended...
- Plasmid vaccination of stable HIV-positive subjects on antiviral treatment results in enhanced CD8 T-cell immunity and increased control of viral "blips"Rob Roy MacGregor
Department of Medicine, University of Pennsylvania School of Medicine, 502 Johnson Pavilion, 36th and Hamilton Walk, Philadelphia, PA 19104 6073, USA
Vaccine 23:2066-73. 2005..04). The decrease in the frequency of transient viremia and failure suggests that DNA immunization with CD8-generating vaccines in HAART-controlled HIV-positive subjects may have therapeutic potential...
- Cyclosporin A provides no sustained immunologic benefit to persons with chronic HIV-1 infection starting suppressive antiretroviral therapy: results of a randomized, controlled trial of the AIDS Clinical Trials Group A5138Michael M Lederman
Case Western Reserve University, University Hospitals of Cleveland, Cleveland, OH 44106, USA
J Infect Dis 194:1677-85. 2006..Although the determinants of immune deficiency and immune restoration in chronic human immunodeficiency virus (HIV)-1 infection are not well understood, immune activation has been proposed as being central to the pathogenesis of HIV...
- Niacin in HIV-infected individuals with hyperlipidemia receiving potent antiretroviral therapyMarisa T Gerber
Division of Infectious Diseases, Department of Internal Medicine, Washington University School of Medicine, Saint Louis, MO, USA
Clin Infect Dis 39:419-25. 2004..Extended release (ER)-niacin therapy, which has been associated with reduced glucose tolerance in human immunodeficiency virus (HIV)-seronegative individuals, has not been evaluated in the HIV-infected population...
- Longitudinal evolution of bone mineral density and bone markers in human immunodeficiency virus-infected individualsKristin Mondy
Division of Infectious Diseases, Department of Internal Medicine, Washington University School of Medicine, St Louis, MO 63108, USA
Clin Infect Dis 36:482-90. 2003..Traditional risk factors and advanced HIV infection play a more significant pathogenic role in the development of osteopenia and osteoporosis associated with HIV infection than do treatment-associated factors...
- HIV and cardiometabolic abnormalities: new perspectives and treatment updatePablo Tebas
University of Pennsylvania, AIDS Clinical Trials Unit, Philadelphia, PA 19104 4283, USA
J Acquir Immune Defic Syndr 49:S77-8. 2008
- HIV-protease inhibitors impair vitamin D bioactivation to 1,25-dihydroxyvitamin DMario Cozzolino
Department of Internal Medicine, Washington University School of Medicine, St Louis, Missouri, USA
AIDS 17:513-20. 2003..The 25- and 1alpha-hydroxylases regulate 1,25(OH) D synthesis and 24-hydroxylase 1,25(OH) D catabolism...
- Insulin resistance and diabetes mellitus associated with antiretroviral use in HIV-infected patients: pathogenesis, prevention, and treatment optionsPablo Tebas
AIDS Clinical Trials Unit, University of Pennsylvania, Philadelphia, PA 19104 4283, USA
J Acquir Immune Defic Syndr 49:S86-92. 2008..Optimization of antiretroviral treatment regimens for HIV-infected patients with or at increased risk for development of abnormalities in glucose metabolism is discussed...
- Enfuvirtide does not require dose adjustment in patients with chronic kidney failure: results of a pharmacokinetic study of enfuvirtide in HIV-1-infected patients with impaired kidney functionPablo Tebas
University of Pennsylvania, Hospital of the University of Pennsylvania, Philadelphia, PA 19104, USA
J Acquir Immune Defic Syndr 47:342-5. 2008..The aim of this study was to examine the influence of kidney disease and hemodialysis on the pharmacokinetics ofenfuvirtide...
- Tenofovir disoproxil fumarate therapy for chronic hepatitis B in human immunodeficiency virus/hepatitis B virus-coinfected individuals for whom interferon-alpha and lamivudine therapy have failedMaria B Ristig
Division of Infectious Diseases, Washington University School of Medicine, St Louis, Missouri 63108, USA
J Infect Dis 186:1844-7. 2002..There was a transient increase of transaminases after the initiation of treatment. No patient developed HBe antibodies. TDF is a very promising drug for the treatment of chronic hepatitis B in HIV-infected individuals...
- Neurokinin-1 receptor antagonist (aprepitant) inhibits drug-resistant HIV-1 infection of macrophages in vitroXu Wang
Division of Allergy and Immunology, Children s Hospital of Philadelphia, Department of Pediatrics, University of Pennsylvania School of Medicine, Philadelphia, PA, USA
J Neuroimmune Pharmacol 2:42-8. 2007..Aprepitant is in clinical use for the prevention of nausea and vomiting associated with cancer chemotherapy or following surgical procedures...
- Is it time to rethink the expanded-access programs for HIV infection?Valerianna Amorosa
University of Pennsylvania, Philadelphia, PA 19104, USA
J Infect Dis 196:974-7. 2007....
- Treating morphologic and metabolic complications in HIV-infected patients on antiretroviral therapy. A consensus statement of an advisory committee of the International Association of Physicians in AIDS CareCarl J Fichtenbaum
IAPAC Mon 11:38-46. 2005..Scientific and clinical research, and other data in published literature and abstracts from scientific conferences were considered by strength of evidence. This document represents the consensus agreement of the Advisory Committee...
- Real-time nucleic acid sequence-based amplification assay to quantify changes in mitochondrial DNA concentrations in cell cultures and blood cells from HIV-infected patients receiving antiviral therapyEveline C Timmermans
Primagen, Amsterdam, The Netherlands
Clin Chem 52:979-87. 2006....
- Effects of the G190A substitution of HIV reverse transcriptase on phenotypic susceptibility of patient isolates to delavirdineErik J Uhlmann
Department of Pathology, Box 8118, Washington University School of Medicine, 660 South Euclid Avenue, St Louis, MO 63110, USA
J Clin Virol 31:198-203. 2004..Cross resistance is common among the non-nucleoside reverse transcriptase inhibitors (NNRTIs). G190A appears in 5-15% of the patients treated with nevirapine or efavirenz who develop clinical resistance...
- Cure of acute hepatitis C in HIV co-infection?Maria B Ristig
J Clin Gastroenterol 38:303. 2004
- Management of chronic hepatitis B in an HIV-positive patient with 3TC-resistant hepatitis B virusMaria Ristig
Division of Infectious Diseases, Hepatology Program, Washington University School of Medicine, St Louis, Missouri, USA
AIDS Patient Care STDS 17:439-42. 2003..The patient was subsequently removed from the liver transplant program and has not suffered from any further hepatic complications...
- Progression of carotid artery intima-media thickening in HIV-infected and uninfected adultsJudith S Currier
Center for Clinical AIDS Research and Education, David Geffen School of Medicine at the University of California, Los Angeles, CA, USA
AIDS 21:1137-45. 2007..To compare the rate of change in intima-media thickness (IMT) of the carotid artery among uninfected subjects and HIV-infected subjects receiving or not receiving protease inhibitor (PI) regimens over a 144 week period...
- Switching to a protease inhibitor-containing, nucleoside-sparing regimen (lopinavir/ritonavir plus efavirenz) increases limb fat but raises serum lipid levels: results of a prospective randomized trial (AIDS clinical trial group 5125s)Pablo Tebas
Division of Infectious Diseases, University of Pennsylvania, Philadelphia, PA 19104, USA
J Acquir Immune Defic Syndr 45:193-200. 2007..Subcutaneous limb fat loss continues to be one the most troubling side effects of long-term antiretroviral regimens. Nucleoside analogues and protease inhibitors (PIs) have been linked to the development of this complication...
- Interventions for body habitus changes associated with HIV infection and its treatmentPablo Tebas
University of Pennsylvania, AIDS Clinical Research Unit, 3451 Walnut Street, Philadelphia, PA 19104, USA
Curr HIV/AIDS Rep 4:86-92. 2007..This review discusses the current management of these complications of HIV and its treatment. For the purpose of clarity in this review, we have divided the interventions according to the predominant phenotype of the individual...
- DNA bar coding and pyrosequencing to identify rare HIV drug resistance mutationsChristian Hoffmann
Department of Microbiology, University of Pennsylvania School of Medicine, 3610 Hamilton Walk, Philadelphia, PA 19104 6076, USA
Nucleic Acids Res 35:e91. 2007....